Colon cancer has overtaken every other cancer as the number one cause of cancer death among Americans under 50. That’s not a typo. A disease once associated almost exclusively with older adults is now killing younger people at a rate that has stunned oncologists and public health officials alike.
The data, reported by The Guardian, draws on the latest figures from the American Cancer Society, which show colorectal cancer climbing to the top of the mortality charts for younger demographics in the United States. For men under 50, it’s already the leading cause of cancer death. For women under 50, it now ranks second only to breast cancer — but the gap is narrowing fast.
This isn’t a sudden spike. It’s the culmination of a trend researchers have tracked for over a decade. Colorectal cancer incidence among adults younger than 55 has been rising roughly 1% to 2% per year since the mid-1990s, according to data from the American Cancer Society’s annual statistics reports. What changed in 2026 is that the mortality figures finally caught up to what epidemiologists had been warning about.
Nobody fully understands why.
That’s the most unsettling part. Theories range from diet and obesity to antibiotic overuse, changes in the gut microbiome, sedentary lifestyles, and environmental exposures. But no single factor has emerged as the definitive driver. Dr. Kimmie Ng, director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute, has been among the most vocal researchers sounding the alarm. She’s pointed to the likelihood of multiple overlapping causes — a convergence of modern lifestyle factors acting on biology in ways we don’t yet fully grasp.
And the diagnostic picture is grim. Younger patients are frequently diagnosed at later stages because neither they nor their doctors expect colon cancer in a 35-year-old. Symptoms like rectal bleeding, persistent abdominal pain, and unexplained weight loss get attributed to hemorrhoids, stress, or irritable bowel syndrome. By the time imaging confirms a tumor, it’s often stage III or IV.
Screening guidelines have already shifted once in response. In 2021, the U.S. Preventive Services Task Force lowered the recommended age for routine colorectal cancer screening from 50 to 45. But many of the patients now dying are in their 30s and even late 20s — well below any screening threshold. So the guideline change, while significant, hasn’t been enough to catch the youngest cases.
Insurance coverage remains a barrier too. Even where guidelines recommend earlier screening, coverage gaps and prior authorization hurdles slow access, particularly for Black and Hispanic Americans, who face disproportionately higher rates of young-onset colorectal cancer. A 2023 study published in JAMA Oncology found that Black patients under 50 had significantly worse survival rates compared to white patients in the same age group, driven in part by later diagnoses and unequal access to treatment.
The political dimension can’t be ignored either. Federal research funding for young-onset colorectal cancer has lagged behind the urgency of the problem. Advocacy groups like the Colorectal Cancer Alliance have pushed Congress for dedicated funding streams, but progress has been incremental at best.
What should industry professionals — from health tech to pharma to insurance — actually take from this?
First, the market for earlier and less invasive screening tools is about to expand significantly. Companies like Exact Sciences, maker of the Cologuard at-home stool DNA test, and Guardant Health, which is developing blood-based screening tests, are positioned at the center of growing demand. The FDA approved Guardant’s Shield blood test for colorectal cancer screening in 2024, and uptake among younger, screening-averse populations could be substantial if pricing and coverage align.
Second, pharmaceutical companies investing in targeted therapies and immunotherapies for colorectal cancer — particularly microsatellite-stable tumors, which represent the majority of cases and respond poorly to current immunotherapies — have a widening addressable market. Merck, Bristol Myers Squibb, and several biotech startups are running trials aimed at cracking this problem.
Third, employers and insurers need to rethink benefit design. Younger workers are the demographic most likely to delay care due to cost concerns. Removing copays for early screening, as the Affordable Care Act mandates for those meeting guideline criteria, is a start. But expanding coverage to symptomatic individuals under 45 who don’t yet meet age-based thresholds would catch more cases early, when treatment is far less expensive and far more effective.
The numbers will keep getting worse before they get better. The American Cancer Society projects continued increases in young-onset colorectal cancer incidence through at least 2030. Without a clearer understanding of root causes and a more aggressive approach to early detection, the body count will grow.
A disease that was once a problem for your grandparents is now a problem for millennials and Gen Z. The science, the policy, and the business models all need to catch up.
WebProNews is an iEntry Publication